While stock splits are far from easy to predict, two names stand out for their potential to do so going forward. Those stocks ...

In today's Pharmalittle roundup, we're reading about a Sarepta setback with its Duchenne drug, the FDA workload causing a ...

Eli Lilly's drug, called eloralintide, helped some patients lose more than 11% of their body weight in three months.

Part of the appeal of amylin analogs is the potential to drive weight loss without causing the same level of tolerability problems as GLP-1 receptor agonists. Lilly reported relatively low rates of ...